Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study

lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma

Luca Arcaini, Thierry Lamy, Jan Walewski, David Belada, Jiri Mayer, John Radford, Wojciech Jurczak, Franck Morschhauser, Julia Alexeeva, Simon Rule, José Cabeçadas, Elias Campo, Stefano A. Pileri, Tsvetan Biyukov, Meera Patturajan, Marie Laure Casadebaig Bravo, Marek Trnĕný, the SPRINT Trial Investigators

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In the mantle cell lymphoma (MCL)-002 study, lenalidomide demonstrated significantly improved median progression-free survival (PFS) compared with investigator's choice (IC) in patients with relapsed/refractory MCL. Here we present the long-term follow-up data and results of preplanned subgroup exploratory analyses from MCL-002 to evaluate the potential impact of demographic factors, baseline clinical characteristics and prior therapies on PFS. In MCL-002, patients with relapsed/refractory MCL were randomized 2:1 to receive lenalidomide (25 mg/day orally on days 1–21; 28-day cycles) or single-agent IC therapy (rituximab, gemcitabine, fludarabine, chlorambucil or cytarabine). The intent-to-treat population comprised 254 patients (lenalidomide, n = 170; IC, n = 84). Subgroup analyses of PFS favoured lenalidomide over IC across most characteristics, including risk factors, such as high MCL International Prognostic Index score, age ≥65 years, high lactate dehydrogenase (LDH), stage III/IV disease, high tumour burden, and refractoriness to last prior therapy. By multivariate Cox regression analysis, factors associated with significantly longer PFS (other than lenalidomide treatment) included normal LDH levels (P < 0·001), nonbulky disease (P = 0·045), <3 prior antilymphoma treatments (P = 0·005), and ≥6 months since last prior treatment (P = 0·032). Overall, lenalidomide improved PFS versus single-agent IC therapy in patients with relapsed/refractory MCL, irrespective of many demographic factors, disease characteristics and prior treatment history.

Original languageEnglish
Pages (from-to)224-235
Number of pages12
JournalBritish Journal of Haematology
Volume180
Issue number2
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Mantle-Cell Lymphoma
Research Personnel
Disease-Free Survival
Therapeutics
gemcitabine
L-Lactate Dehydrogenase
Demography
Chlorambucil
lenalidomide
Cytarabine
Tumor Burden
History
Regression Analysis

Keywords

  • lenalidomide
  • mantle cell lymphoma
  • non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study : lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. / Arcaini, Luca; Lamy, Thierry; Walewski, Jan; Belada, David; Mayer, Jiri; Radford, John; Jurczak, Wojciech; Morschhauser, Franck; Alexeeva, Julia; Rule, Simon; Cabeçadas, José; Campo, Elias; Pileri, Stefano A.; Biyukov, Tsvetan; Patturajan, Meera; Casadebaig Bravo, Marie Laure; Trnĕný, Marek; the SPRINT Trial Investigators.

In: British Journal of Haematology, Vol. 180, No. 2, 01.01.2018, p. 224-235.

Research output: Contribution to journalArticle

Arcaini, L, Lamy, T, Walewski, J, Belada, D, Mayer, J, Radford, J, Jurczak, W, Morschhauser, F, Alexeeva, J, Rule, S, Cabeçadas, J, Campo, E, Pileri, SA, Biyukov, T, Patturajan, M, Casadebaig Bravo, ML, Trnĕný, M & the SPRINT Trial Investigators 2018, 'Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma', British Journal of Haematology, vol. 180, no. 2, pp. 224-235. https://doi.org/10.1111/bjh.15025
Arcaini, Luca ; Lamy, Thierry ; Walewski, Jan ; Belada, David ; Mayer, Jiri ; Radford, John ; Jurczak, Wojciech ; Morschhauser, Franck ; Alexeeva, Julia ; Rule, Simon ; Cabeçadas, José ; Campo, Elias ; Pileri, Stefano A. ; Biyukov, Tsvetan ; Patturajan, Meera ; Casadebaig Bravo, Marie Laure ; Trnĕný, Marek ; the SPRINT Trial Investigators. / Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study : lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. In: British Journal of Haematology. 2018 ; Vol. 180, No. 2. pp. 224-235.
@article{044c852d4b87483a8644ddb6cce639a6,
title = "Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma",
abstract = "In the mantle cell lymphoma (MCL)-002 study, lenalidomide demonstrated significantly improved median progression-free survival (PFS) compared with investigator's choice (IC) in patients with relapsed/refractory MCL. Here we present the long-term follow-up data and results of preplanned subgroup exploratory analyses from MCL-002 to evaluate the potential impact of demographic factors, baseline clinical characteristics and prior therapies on PFS. In MCL-002, patients with relapsed/refractory MCL were randomized 2:1 to receive lenalidomide (25 mg/day orally on days 1–21; 28-day cycles) or single-agent IC therapy (rituximab, gemcitabine, fludarabine, chlorambucil or cytarabine). The intent-to-treat population comprised 254 patients (lenalidomide, n = 170; IC, n = 84). Subgroup analyses of PFS favoured lenalidomide over IC across most characteristics, including risk factors, such as high MCL International Prognostic Index score, age ≥65 years, high lactate dehydrogenase (LDH), stage III/IV disease, high tumour burden, and refractoriness to last prior therapy. By multivariate Cox regression analysis, factors associated with significantly longer PFS (other than lenalidomide treatment) included normal LDH levels (P < 0·001), nonbulky disease (P = 0·045), <3 prior antilymphoma treatments (P = 0·005), and ≥6 months since last prior treatment (P = 0·032). Overall, lenalidomide improved PFS versus single-agent IC therapy in patients with relapsed/refractory MCL, irrespective of many demographic factors, disease characteristics and prior treatment history.",
keywords = "lenalidomide, mantle cell lymphoma, non-Hodgkin lymphoma",
author = "Luca Arcaini and Thierry Lamy and Jan Walewski and David Belada and Jiri Mayer and John Radford and Wojciech Jurczak and Franck Morschhauser and Julia Alexeeva and Simon Rule and Jos{\'e} Cabe{\cc}adas and Elias Campo and Pileri, {Stefano A.} and Tsvetan Biyukov and Meera Patturajan and {Casadebaig Bravo}, {Marie Laure} and Marek Trnĕn{\'y} and {the SPRINT Trial Investigators}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/bjh.15025",
language = "English",
volume = "180",
pages = "224--235",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "2",

}

TY - JOUR

T1 - Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study

T2 - lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma

AU - Arcaini, Luca

AU - Lamy, Thierry

AU - Walewski, Jan

AU - Belada, David

AU - Mayer, Jiri

AU - Radford, John

AU - Jurczak, Wojciech

AU - Morschhauser, Franck

AU - Alexeeva, Julia

AU - Rule, Simon

AU - Cabeçadas, José

AU - Campo, Elias

AU - Pileri, Stefano A.

AU - Biyukov, Tsvetan

AU - Patturajan, Meera

AU - Casadebaig Bravo, Marie Laure

AU - Trnĕný, Marek

AU - the SPRINT Trial Investigators

PY - 2018/1/1

Y1 - 2018/1/1

N2 - In the mantle cell lymphoma (MCL)-002 study, lenalidomide demonstrated significantly improved median progression-free survival (PFS) compared with investigator's choice (IC) in patients with relapsed/refractory MCL. Here we present the long-term follow-up data and results of preplanned subgroup exploratory analyses from MCL-002 to evaluate the potential impact of demographic factors, baseline clinical characteristics and prior therapies on PFS. In MCL-002, patients with relapsed/refractory MCL were randomized 2:1 to receive lenalidomide (25 mg/day orally on days 1–21; 28-day cycles) or single-agent IC therapy (rituximab, gemcitabine, fludarabine, chlorambucil or cytarabine). The intent-to-treat population comprised 254 patients (lenalidomide, n = 170; IC, n = 84). Subgroup analyses of PFS favoured lenalidomide over IC across most characteristics, including risk factors, such as high MCL International Prognostic Index score, age ≥65 years, high lactate dehydrogenase (LDH), stage III/IV disease, high tumour burden, and refractoriness to last prior therapy. By multivariate Cox regression analysis, factors associated with significantly longer PFS (other than lenalidomide treatment) included normal LDH levels (P < 0·001), nonbulky disease (P = 0·045), <3 prior antilymphoma treatments (P = 0·005), and ≥6 months since last prior treatment (P = 0·032). Overall, lenalidomide improved PFS versus single-agent IC therapy in patients with relapsed/refractory MCL, irrespective of many demographic factors, disease characteristics and prior treatment history.

AB - In the mantle cell lymphoma (MCL)-002 study, lenalidomide demonstrated significantly improved median progression-free survival (PFS) compared with investigator's choice (IC) in patients with relapsed/refractory MCL. Here we present the long-term follow-up data and results of preplanned subgroup exploratory analyses from MCL-002 to evaluate the potential impact of demographic factors, baseline clinical characteristics and prior therapies on PFS. In MCL-002, patients with relapsed/refractory MCL were randomized 2:1 to receive lenalidomide (25 mg/day orally on days 1–21; 28-day cycles) or single-agent IC therapy (rituximab, gemcitabine, fludarabine, chlorambucil or cytarabine). The intent-to-treat population comprised 254 patients (lenalidomide, n = 170; IC, n = 84). Subgroup analyses of PFS favoured lenalidomide over IC across most characteristics, including risk factors, such as high MCL International Prognostic Index score, age ≥65 years, high lactate dehydrogenase (LDH), stage III/IV disease, high tumour burden, and refractoriness to last prior therapy. By multivariate Cox regression analysis, factors associated with significantly longer PFS (other than lenalidomide treatment) included normal LDH levels (P < 0·001), nonbulky disease (P = 0·045), <3 prior antilymphoma treatments (P = 0·005), and ≥6 months since last prior treatment (P = 0·032). Overall, lenalidomide improved PFS versus single-agent IC therapy in patients with relapsed/refractory MCL, irrespective of many demographic factors, disease characteristics and prior treatment history.

KW - lenalidomide

KW - mantle cell lymphoma

KW - non-Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=85035217950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035217950&partnerID=8YFLogxK

U2 - 10.1111/bjh.15025

DO - 10.1111/bjh.15025

M3 - Article

VL - 180

SP - 224

EP - 235

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -